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Abstract
Background: The Pathway Ontology (PW) developed at the Rat Genome Database (RGD), covers all types of
biological pathways, including altered and disease pathways and captures the relationships between them within
the hierarchical structure of a directed acyclic graph. The ontology allows for the standardized annotation of rat,
and of human and mouse genes to pathway terms. It also constitutes a vehicle for easy navigation between gene
and ontology report pages, between reports and interactive pathway diagrams, between pathways directly
connected within a diagram and between those that are globally related in pathway suites and suite networks.
Surveys of the literature and the development of the Pathway and Disease Portals are important sources for the
ongoing development of the ontology. User requests and mapping of pathways in other databases to terms in the
ontology further contribute to increasing its content. Recently built automated pipelines use the mapped terms to
make available the annotations generated by other groups.
Results: The two released pipelines – the Pathway Interaction Database (PID) Annotation Import Pipeline and the
Kyoto Encyclopedia of Genes and Genomes (KEGG) Annotation Import Pipeline, make available over 7,400 and
31,000 pathway gene annotations, respectively. Building the PID pipeline lead to the addition of new terms within
the signaling node, also augmented by the release of the RGD “Immune and Inflammatory Disease Portal” at that
time. Building the KEGG pipeline lead to a substantial increase in the number of disease pathway terms, such as
those within the ‘infectious disease pathway’ parent term category. The ‘drug pathway’ node has also seen
increases in the number of terms as well as a restructuring of the node. Literature surveys, disease portal
deployments and user requests have contributed and continue to contribute additional new terms across the
ontology. Since first presented, the content of PW has increased by over 75%.
Conclusions: Ongoing development of the Pathway Ontology and the implementation of pipelines promote an
enriched provision of pathway data. The ontology is freely available for download and use from the RGD ftp site at
ftp://rgd.mcw.edu/pub/ontology/pathway/ or from the National Center for Biomedical Ontology (NCBO) BioPortal
website at http://bioportal.bioontology.org/ontologies/PW.
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The Pathway Ontology (PW) originated and is being de-
veloped at the Rat Genome Database (RGD) [1]. Its goal
is to cover any type of biological pathway, including al-
tered and disease pathways, and to capture the relation-
ships between them within the hierarchical structure of
a controlled vocabulary or ontology. The building of bio-
logical ontologies as directed acyclic graphs (DAG) and
the use of structured or controlled vocabularies was first
advanced and implemented by the Gene Ontology (GO)
project [2,3]. Many bio-ontologies have been developed
since [4], as witnessed by the ever-growing number sub-
mitted to and made available at the National Center for
Biomedical Ontology (NCBO) BioPortal [5,6]. Several
ontologies, including the Pathway Ontology, are being
developed at RGD ([7], in the “Biomedical Ontologies”
thematic series of the Journal of Biomedical Semantics).
Within the structure of a DAG, terms have defined rela-
tionships to one another and a particular term can have
more than one parent. This means that there can be
more than one path in the ontology tree from a broader,
more general parent term to a more specialized child
term. Within the tree structure, terms are nodes whose
names designate the class(es) they represent and which
are connected by edges that represent the relationship(s)
between them. In PW, a node is the network/pathway
class it stands for, and its features and aspects are cap-
tured in the definition. A pathway is a set of inter-
connected reactions and interactions whose delineation
and scope are used as a model for exploring and study-
ing, describing and understanding the working of and
relationships between biomolecules within a context.
The categories or types of pathways are conceptualized
and referenced in the scientific literature and repre-
sented in pathway databases such as the Kyoto
Encyclopedia of Genes and Genomes (KEGG), the
Pharmacogenomics Knowledge Base (PharmGKB), the
Small Molecule Pathway Database (SMPDB) and Wiki-
Pathways, among others [8-11].
The pathway ontology structure
The first of the main five nodes of the ontology, the meta-
bolic node, contains networks/pathways that stand for/rep-
resent the set of reactions underlying the transformation of
compounds. The set of reactions/interactions underlying
the coordinated responses that maintain the cellular/tissue
and/or organ/organismal status quo and homeostasis are
placed under the regulatory node. The set of reactions/in-
teractions initiated or triggered by a binding/molecular
interaction/conformational change event are found under
the signaling node. The set or sets of interactions where
one or more are deviant and represent the system’s perturb-
ation(s) fall under the disease node. Finally, the set or sets
of reactions/interactions representing the system’s response
to and handling of treatment(s) geared towards dealing with
those perturbation(s) are housed in the drug node. Thus,
the main nodes of the Pathway Ontology are: metabolic,
regulatory, signaling, disease and drug pathway (Figure 1A).
Two types of relationships are being used in the ontology:
“is_a” and “part_of”. For instance, insulin and glucagon are
peptide hormones whose signaling - ‘insulin signaling path-
way’ and ‘glucagon signaling pathway’, are children terms in
an ‘is-a’ relationship to the parent term ‘peptide and protein
hormone signaling pathway’. The two signaling pathways
which are initiated in response to high levels of circulating
glucose – ‘insulin signaling pathway’, or low – ‘glucagon sig-
naling pathway’, and whose engagement of intracellular cas-
cades aims at restoring the normal physiological levels of
glucose, are also in a “part-of” relationship to the ‘glucose
homeostasis pathway’ term, along with other pertinent
terms. Insulin also plays important roles in energy homeo-
stasis. In the brain, insulin (and leptin) act to increase the
expression of appetite-decreasing Pomc while decreasing
the expression of appetite-stimulating Agrp genes. The
‘peptide and protein hormone signaling pathway’ term is in
turn a child of the more general term ‘hormone signaling
pathway’, as other classes of compounds with very different
physico-chemical properties can also act as hormones. For
instance, the steroid hormones and the eicosanoids which,
as the names suggest, are hormones, are lipid molecules.
The signaling pathways they initiate are children of the
‘lipid hormone signaling pathway’ term which in turn, is a
sibling of ‘peptide and protein hormone signaling pathway’
and child of ‘hormone signaling pathway’ terms (Figure 1B).
The nodes are not disjoint and a given pathway class can
be the child of terms residing in different nodes, as the ex-
amples of insulin and glucagon signaling above show. The
‘peptide and protein hormone signaling pathway’ and the
‘glucose homeostasis pathway’ are both parents of the sig-
naling pathways of insulin and glucagon, albeit with differ-
ent relationships to their children; the two parent terms are
within the signaling and regulatory nodes, respectively. The
‘energy homeostasis pathway’ term is also a parent of insu-
lin signaling and like glucose homeostasis, it is within the
regulatory node (Figure 1C).
The “pathway” and the “process” concepts, although at
times interchangeably used, are distinct. A pathway conveys
the idea of a set of interacting molecules, of the reactions
and interactions underlying its functioning. A process on
the other hand, conveys the idea of the end result, the con-
clusion of a plan of action, whether the consequence of the
combined work that the set of reactions and interactions
produces, in the case of a simpler one, or in the case of a
more complex one, the combined work of pathways that
contribute to or in some fashion modulate the end result.
At the same time, a given pathway can participate in and/
or regulate several processes [12]. In the Biological Process
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(BP) ontology of GO there are metabolic and other process
terms that map to KEGG pathways and to terms in PW.
For instance, the formation of a fatty acid molecule is the
‘fatty acid biosynthetic process’ term in GO; it is the ‘fatty
acid biosynthetic pathway’ term and the ‘fatty acid biosyn-
thesis’ entry in PW and at KEGG, respectively. While the
phrasing is similar in GO, PW and KEGG, the term repre-
sents a process in GO, a pathway in PW and the KEGG
database. KEGG is a primary source for metabolic pathways
and projects such as databases and ontologies that in some
fashion represent metabolism are going to exhibit a sharing,
or an overlapping of terms/entries naming, but not an over-
lapping of concepts and/or contexts. Likewise, there are sig-
naling pathway terms in BP that relate to similar terms in
the signaling pathway node of PW and map to entries in
pathway databases such as KEGG and others. However, the
positions of and relationships between such terms are dif-
ferent, as are the perspectives of the two ontologies.
Disease and altered pathways
The provision of terms for the altered versions of path-
ways and the representation of disease pathways and dia-
grams as collections of altered pathways are unique to
PW and its use at RGD. An altered pathway is one
where defects in one or several components of the path-
way affect its normal functioning with potential implica-
tions for a diseased phenotype. The severity of an
altered pathway or the convergence of several altered
pathways can overcome the ability of the system to ad-




Figure 1 The pathway ontology main nodes and positions of selected terms. A. The five nodes of the Pathway Ontology. B. The term ‘lipid
hormone signaling pathway’ in the ontology showing the parent, siblings and children terms. C. The term ‘insulin signaling pathway’ in the
ontology showing the position of the term within the tree. ‘Insulin signaling pathway’ is in a part_of relationship to the ‘glucose’ and ‘energy
homeostasis pathway’ terms within the regulatory node and in an is_a relationship to ‘peptide and protein hormone signaling pathway’ term
within the signaling node.
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diseases from a network- rather than a gene-centric per-
spective, from the systems level of pathway cross-talk
and alterations within, is an approach increasingly being
considered [13-15].
As an example, a large-scale study carried out on a
number of pancreatic tumors identified several sets of
genes that were altered in the majority of tumors. Of
these, many were associated with core signaling path-
ways and altered in 67% to 100% of tumors [16]. Perhaps
not surprisingly, these are pathways important for
growth and proliferation and in some cases, also known
to be oncogenic (Figure 2). What may be intriguing is
the relatively large number of altered pathways and one
is tempted to wonder/speculate whether it is this num-
ber and the combinations that result from it, that over-
come the ability of the system to adjust and/or recover
and render the condition intractable. The pancreatic
cancer pathway diagram presents the main pathways al-
tered in the condition with the culprit genes shown
color coded. Additional links to a list of miRNAs
(microRNAs) aberrantly expressed in pancreatic tumors
and to the Cancer Portal at RGD are provided (see
Figure 2).
Pathway annotations, interactive pathway diagrams,
pathway suites and suite networks
The use of the ontology allows for the standardized an-
notation of rat, human and mouse genes to pathway
terms. Generally, annotations are made for the term ra-
ther than on a gene-by-gene basis; thus, what is being
targeted for annotation is the pathway itself – like the
ontology the overall pathway curation process is
network-centered [12,17]. Importantly, the ontology pro-
vides the navigational means to access pathway annota-
tions, interactive pathway diagrams, pathway suites and
suite networks as well as a variety of tools, from many
entry points. A pathway suite is a collection of pathways
that revolves around a common concept or is globally
Figure 2 Pancreatic cancer pathway diagram. The interactive pathway diagram page for the ‘pancreatic cancer pathway’. The altered
pathways associated with the condition are shown as gray rectangles that link to the ontology report(s) for the those terms. Culprit genes within
the pathways are shown color-coded (default is red). The icon for the microRNAs (miRNA) with potential roles in pancreatic cancer links to a page
where several down- and up-regulated miRNAs are shown with some targets listed and with links to their report pages in RGD and the microRNA
database (MiRBase). The icon for the condition links to the Cancer Disease Portal in RGD.
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related. If two (or more) pathway suites relate in some
fashion, they constitute a suite network. For instance,
the ‘Glucose Homeostasis Pathway Suite Network’
brings together the suite dedicated to the various meta-
bolic pathways involving glucose and the one dedicated
to the contributing signaling and regulatory pathways.
Together, the pathway ontology, the pathway annota-
tions and the graphical representations of pathways,
constitute the elements of the Pathway Portal [12,17,18],
an important project at the Rat Genome Database
[19,20]. Pathway, along with disease, phenotype and bio-
logical process, are the major concepts around which
the Disease Portals are built and are entry points to
access the data they contain. The Disease and Pathway
Portals can be accessed from the main homepage of
RGD (Figure 3A). The “Pathways” entry point leads to
the Molecular Pathways link which houses the collection
of interactive pathway diagrams and suites that RGD
publishes. This entry point also provides access to path-
way related publications by members of RGD as well as
other information and data links (Figure 3B).
An ontology search, accessed through the “Function”
entry point (see Figure 3A), brings up all the ontologies
that have terms which contain the keyword(s) used. Se-
lection of an ontology will show the terms containing
the keyword(s) with the option to search the tree or view
A
B
Figure 3 Pathway portal data access. A. Rat Genome Database homepage with the main entry points to its content; the “Pathways” and
“Function” entry points described in the text, are circled. B. Accessing the “Pathways” entry point and entries within.
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the annotations. Selecting the branch icon to the left of
a term brings up a browser result showing the parent,
siblings and children of the term. The browser has been
developed at RGD and recently updated to indicate
whether interactive pathway diagrams are available or
not for terms and/or their children in the form of a
boxed “D” of darker or paler green color, respectively
(see Figure 1A-B). Any dark green “D” box links to that
interactive diagram page. In addition, if the searched
term has a diagram, a small icon will be shown in the
term entry, to the right of the term description; it will
also link to the diagram page. [The boxed “A” in
Figure 1A-B denotes the presence of annotations].
Selecting a term brings up an ontology report page with
the GViewer tool – a genome-wide view of rat chromo-
somes with genes annotated to the term, a tabular list of
genes annotated to the term by species with links to re-
spective gene report pages and a diagram showing the
paths to the root term in the ontology tree. If there is an
interactive pathway diagram for the chosen term, an
icon is present at the top of the page to the right of the
diagram and it links to the pathway diagram page.
Every diagram page consists of several sections. The
first provides an in-depth, expandable description of the
pathway and the diagram itself whose objects link to
their report pages in RGD (genes, chemicals, pathways)
or other websites. Beneath that is a tabular list of anno-
tated genes by species with each entry linking to its re-
port page and other links. As applicable, the altered
version of the pathway and additional elements in the
diagram can also be found in this section. The next sec-
tion contains tabular lists of genes in the pathway that
have been annotated to disease, other pathway and
phenotype terms with links to corresponding report
pages. The user has the option of toggling between
terms and genes and can follow links to ontology report
pages for terms and to gene report pages for genes.
Rounding out the diagram page are a list of references
with links to the RGD reference report page (which
links to PubMed), and a view of the ontology tree
(Figure 4A-D). Pathways that are related, triggered by or
directly connected to the featured pathway are shown in
the diagram and they link to the ontology report for the
term. In Figure 2 and 4A, the gray rectangles are path-
way terms and they link to the corresponding ontology
report pages, with links as described. If, as mentioned, a
number of pathways revolve around a common concept
or relate in a global fashion, they are presented in path-
way suites and suite networks which offer an instant
snapshot of their relatedness. For instance, the folate
cycle and the folate mediated one-carbon pathways, the
methionine, homocysteine and other metabolic pathways
are components of the ‘Methionine, Homocysteine, Fol-
ate and Related Metabolites Pathway Suite’. The pathway
suites dedicated to the pro- and the anti-inflammatory
signaling pathways are the two arms of the ‘Balancing
Inflammatory Responses Pathway Suite Network’ (see
also the ‘Glucose Homeostasis Pathway Suite Network
above). A tripartite pathway suite network dedicated to
molecular mechanisms of blood pressure regulation has
also recently been released. Thus, whether from within
individual diagrams or via suites and suite networks, the
user can travel the pathway landscape, from detailed
examination to broad overview.
Primarily the review and research literature published
in major journals, but also database searches and users
requests, are sources for the addition of terms in the
ontology, the representation of pathways in interactive
diagrams and the annotation of genes within pathways.
In addition, the restructuring of the drug node and pipe-
lines for importing pathway data from external databases
helped, and new disease portal releases continue to help
increase and improve upon the content, structure and
use of the ontology. These more recent developments
are presented in the next section.
Results and discussion
To further expand the information content that the
Pathway Portal provides, RGD has recently developed
automated pipelines to bring in data from external
sources. The building of the pipelines, along with the
ongoing development of the ontology and the deploy-
ment of disease portals, has led to further developments
within the pathway ontology. Many of the new terms
added for the pipelines are within the signaling and dis-
ease pathway nodes of the ontology. The restructuring
of the drug pathway node was accompanied by the
addition of new terms, particularly for the drugs within
the antineoplastic category. User requests led to addi-
tions across the metabolic, signaling and regulatory
pathway nodes. Since last presented [17], the ontology
has seen the addition of more than 640 new terms
across all nodes of the ontology, representing ~44% of
the current ontology content. As of the time of this writ-
ing, the ontology holds over 1,480 terms (see Table 1 for
ontology statistics).
Pathway interaction database (PID) pipeline
The Pathway Interaction Database (PID) [21] at the Na-
tional Cancer Institute has been offering a collection of
human regulatory and signaling pathways and has been
using the regulatory and signaling nodes of PW to allow
its users to browse these pathways by categories. To load
and access the manually curated human PID annota-
tions, RGD decided to implement a pipeline that would
automatically bring in the data. PID pathway identifiers
(IDs) were added as synonyms in the Pathway Ontology.
As PID was using higher level PW terms to categorize
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its pathways, names/terms in PID not present in PW
were added. Building of the PID pipeline lead to the
addition of several new terms within the signaling and
regulatory nodes of PW. For instance, ‘ceramide signaling
pathway’ and ‘sphingosine 1-phosphate signaling path-
way’ were added to the ontology under ‘signaling
pathway involving second messengers’ and a term for
‘lipid signaling pathway’ was added, as ceramide and
sphingosine 1-phosphate are lipids. As mentioned, in the
DAG structure, a child term can have more than one
parent term. The two new terms are children of both
‘lipid signaling pathway’ and of ‘signaling pathway in-
volving second messengers’. If more than one entry in
PID was related to a term, all pertinent PID entry IDs
were added as synonyms to PW. As an example,




Figure 4 The anatomy of an interactive pathway diagram page. A. The top of the page shows the beginning of the description with the
option of viewing the whole text and the diagram below it. B. The genes in the pathway are shown by species in a tabular form with various
link options. C. Genes in the pathway that have disease annotations are shown in a table that can be toggled between diseases, alphabetically
listed, with the associated genes shown to the right (default), and genes, alphabetically listed, with the associated diseases shown to the right.
D. Genes in the pathway that have annotations to other pathways are shown in a table that can be toggled between pathways, alphabetically
listed, with the associated genes shown to the right (default), and genes, alphabetically listed, with the associated pathways shown to the right.
The last section of the diagram page has the reference list as well as a view of the ontology tree (not shown).
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second messenger can also signal extracellularly as a lig-
and for several G protein coupled receptors. PID has
separate entries for the receptors and they were added
as synonyms to assure that all PID annotations pertinent
to this lipid signaling were brought in. Other examples
include terms for signaling by the members of the cad-
herin superfamily which increased the content under the
‘cell-cell signaling pathway’ parent term or those that
increased the content under the ‘proteoglycan signaling
pathway’ parent term. An accompanying literature
search for the provision of definitions also lead to the
addition of new terms. For instance, the PID entries for
cadherin signaling are only for the E- and N-cadherins
of the “classical” branch of the superfamily. Terms for
the other branches of the cadherin superfamily were
added at the same time.
The pipeline extracted the data from the PID mas-
ter file and mapped it to PW terms via synonyms.
51 individual PW terms have synonyms that map to
PID entries. The human genes in the PID file were
matched to human genes in RGD and assigned to
the mapped PW term with evidence code EXP
(Inferred from Experiment). The annotations were
propagated to the rat and mouse orthologs with the
evidence code ISO (Inferred from Sequence Orthol-
ogy). The use of evidence codes to indicate how the
annotation of a gene to an ontology term is sup-
ported originates from the development of GO. Evi-
dence codes are used for all ontology terms and
objects that are annotated to them at RGD. Over
7,400 pathway gene annotations from PID are avail-
able at RGD (See Table 2 for number of mapping
terms and annotations). In a gene report page, PID
annotations are seen under the “Molecular Pathway
Annotations” category with the source (PID) shown
and also in the ‘External Database Link’ category
under PID (and/or KEGG, as applicable, described
below). The pathway(s) listed in the “Molecular
Pathway Annotations” category link to the ontology
report pages for those terms. The pathway(s) listed
under the ‘External Database Link’ link to their en-
tries at PID. Generally, RGD pipelines run on a
weekly basis. Unfortunately, a few months after RGD
released the pipeline, PID announced that it was no
longer active and was retired in September 2013.
The Kyoto encylopedia of genes and genomes (KEGG)
pipeline
The Kyoto Encyclopedia of Genes and Genomes (KEGG) is
a large and important pathway resource and provides a host
of other biological information across a spectrum of phyla
and species [22,23]. The KEGG Annotation Import Pipeline
is based on a one-time download before the site changed
its license and limited access to its data. KEGG map IDs
were added as synonyms to the matching terms in PW and
new ones were added, as necessary. For instance, KEGG
has disease pathways by categories, including substance
abuse and infectious diseases, which at the time were not
represented in the ontology. These categories were added
as parent terms with the corresponding children terms and
the KEGG pathway map IDs as synonyms. Many individual
child terms were added for the ‘infectious disease pathway’
category. KEGG and the literature were consulted to pro-
vide definitions that succinctly describe the condition and
point to host pathway(s) and/or process(es) the condition
may counteract or affect. Another new category was added
for the ‘immune disease pathway’ with children terms for
the entries at KEGG.
Pathway data was extracted from the KEGG master file
and mapped to PW terms via synonyms. 215 PW terms
have synonyms mapping to entries in KEGG. Genes from
the KEGG annotations in the species files were matched to
the RGD genes for rat, human and mouse and assigned to
the corresponding PW term with evidence code IEA (In-
ferred from Electronic Annotation). Over 31,000 pathway
gene annotations from KEGG are available at RGD. (See
Table 2 for number of mapping terms and annotations).
KEGG pathway annotations on RGD gene report pages are
seen in a manner similar to the PID annotations.
Drug pathway node – restructuring and applications
The drug pathway node was expanded to contain parent
terms for categories as listed by the Anatomical Thera-
peutic Chemical (ATC) Classification System. The system
is used for the classification of drugs and is controlled by
the World Health Organization (WHO) Collaborating
Centre for Drug Statistics Methodology [24,25]. In the ATC
system, compounds are divided into groups depending on
the organ or system upon which they act and their thera-
peutic, pharmacological and chemical characteristics. The
main anatomical group represents the first level of the
code. The second level of the code indicates the main
Table 1 A summary of PW aspects and structure
Number of class nodes Relationship_types Total number of terms Total number of annotations Depth Definition coverage
5 is_a; part_of 1,485 49,103 10 86%
Table 2 A summary of term mappings and pathway









215 31,012 51 7,408
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therapeutic group while levels three to five indicate the
therapeutic/pharmacological, the chemical/therapeutic/.
pharmacological subgroups and the chemical substance, re-
spectively. Initially, drug pathway terms were added directly
under the main drug node. With the drug node expanding,
the addition of terms for the first level categories as place
holders for individual drug pathway terms was a necessary
step to assure the consistency and internal logic of the
ontology. In addition, a number of individual drug pathway
terms were added, particularly for drugs within the ‘cardio-
vascular system drug pathway’ branch and for drugs in the
‘antineoplastic and immunomodulatory drug pathway’
branch. Many of the currently available disease pathway
interactive diagrams represent cancer types and addition of
diagrams for drug(s) used in cancer treatment allows link-
ing the condition and the drug pathways. For each drug
pathway term, children terms are added to represent the
pharmacokinetics pathway (how the system processes the
drug) and the pharmacodynamics pathway (how the drug
acts upon the system). Examples include, but are not lim-
ited to ezetimibe, lomitapide and losartan drug pathways in
the ‘cardiovascular system drug pathway’ branch, or axi-
tinib, sunitinib, pazopanib, to name a few, in the ‘antineo-
plastic and immunomodulatory drug pathway’ branch. Of
these, axitinib and losartan have interactive pathway dia-
grams currently available. As the node is expected to fur-
ther expand including the development of new pipelines
for data import from drug pathway databases, it is likely
that the second level and/or other levels of ATC will be
added as necessary in order to make both searching the tree
and finding the pertinent entries easy while maintaining the
consistency of the ontology. However, this and/or other re-
structuring involve branching off the tree and do not
change the overall topology or architecture of the ontology.
The ATC system can be browsed at KEGG [26].
As described, a disease pathway is represented by the
altered pathways implicated in the disease process (see
Figure 2). Various other elements are also provided on
the disease pathway diagram including drugs and dis-
eases, microRNAs whose expression is deregulated in
tumor tissues, and other candidate genes, as applicable
and/or available. As an example, in the case of renal cell
carcinoma (RCC), alteration of the hypoxia inducible
factor pathway is the major factor and several drugs are
being used for treatment. Many of these drugs target the
genes whose expression is controlled by hypoxia indu-
cible transcription factors, such as components of the
vascular endothelial growth factor (VEGF) pathway. Sev-
eral drugs target the VEGF receptors; one such drug is
axitinib. In the diagram page for this disease pathway,
the icon for the drugs links to a page that lists them with
links to the chemical entry pages (at RGD or elsewhere,
as available) and to the available drug pathway(s). The
icon for miRNA with potential roles in RCC and the one
for other RCC candidate genes link to similar pages list-
ing the pertinent entries. Such list pages are created in a
Content Management System (CMS) and the url is
added in the information for the object(s) created in the
Ariadne Genomics Pathway Studio tool. The diagram for
the axitinib drug pathway shows the overall actions of
the drug along with side effects and links to associated
pathway pages.
In many instances, the pharmacokinetics of drugs is
investigated in human liver microsomes. The micro-
somal enzymes belong to the families of the cytochro-
mone P450 superfamily and are involved in drugs and
xenobiotic metabolism. Some enzyme family members
have broader substrate specificity, are less conserved and
present considerable species as well as inter-individual
variation [27,28]. In this case, annotations are not propa-
gated to orthologs. For each altered version of a path-
way, the normal pathway is built first. A pathway
diagram page provides the option of adding the altered
version of that pathway, if one exists. A direct link to
the normal pathway is made available from the descrip-
tion on the altered pathway diagram page. Thus, users
can see both the regular and the affected pathways, in
this case the hypoxia inducible factor pathway and its al-
tered version (Figure 5A, B). Culprit genes are color-
coded in both the disease and the altered pathway dia-
grams (Figure 5B, see also Figure 2).
Other developments
At the time the PID pipeline was built, RGD was in the
process of developing the Immune and Inflammatory Dis-
ease Portal. As a result, the chemokine and the cytokine
mediated signaling branches of the ontology were expanded
to incorporate most if not all the chemokine and cytokine
families or groups as parent terms with their corresponding
members as children terms. The category ‘immune disease
pathway’ was added as described in the KEGG pipeline sec-
tion. More terms were added to cover the metabolism of vi-
tamins. The deployment of new diagrams can also lead to
increases in the content of and/or improvement in the
consistency of the ontology. As an example, in the process
of building the pathway diagrams to be included in the
‘Methionine, Homocysteine, Folate and Related Metabolites
Pathway Suite’ both restructuring and additions have been
made. In the transsulfuration pathway of homocysteine me-
tabolism, hydrogen sulfide is a by-product of cysteine ca-
tabolism. While elevated levels can be toxic, the gaseous
molecule can also act as a signaling molecule. ‘Hydrogen
sulfide mediated signaling pathway’ and its parent ‘gaso-
transmitter mediated signaling pathway’ were therefore
added to the ontology. Altered terms for the children of fol-
ate metabolism were also added, as several conditions
resulting from defects in these pathways have been
documented.
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The development of the latest deployed disease portal
– the Renal Disease Portal also contributed to the
addition of terms across disease and drugs branches,
among others. For instance, the above mentioned RCC
pathway and the drugs that target it, such as axitinib,
and the terms for the altered versions of the hypoxia in-
ducible factor and the citric acid pathways, are examples
of terms added for this portal. Currently, a portal for
sensory organ diseases is under development that is ex-
pected to further contribute to the development of the
ontology.
Users of the Pathway Ontology can contact RGD for
requests of new terms and/or questions they might have.
A recent request originally made for one pathway term
has expanded into a large request list that further con-
tributed to the increase in the content of the ontology
within the metabolic, signaling and regulatory nodes.
Children terms to parent entries within the carbohy-
drate, lipid and secondary metabolite branches of the
metabolic node were added. The ‘metal’ and ‘non-metal
ion transport pathway’ terms were created as children of
the new parent term ‘ion transport pathway’ within the
regulatory node, to accommodate the request for ‘chlor-
ide transport pathway’, a non-metal. Terms for several
peptide hormone, growth and transcription factor signal-
ing pathways were added within the respective parent
A
B
Figure 5 Hypoxia inducible factor pathway. A. The normal functioning of the ‘hypoxia inducible factor pathway’. B. The ‘altered’ version of the
‘hypoxia inducible factor pathway’.
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terms in the signaling node. As of the time of this writ-
ing, other requests have been made with the addition of
new terms in progress. The Pathway Ontology is species
independent and terms for pathways that take place in
species other than mammal or animal can be found. For
instance, the pathways of secondary metabolites – a cat-
egory within the metabolic node, are mostly present in
microorganisms and/or plants. Likewise, the biodegrad-
ation of xenobiotics – also a category within the meta-
bolic node, is the realm of microorganisms possessing
the enzymes that are capable of breaking down chemi-
cals generally resistant to degradation. Several user re-
quests were for metabolic pathway terms present in
plants and microorganisms. For instance, the biosyn-
thesis of momilactone – a diterpene produced by rice, of
cellulose – a polysaccharide and structural component
of green plants cell walls, of lycopene – a carotene found
in fruit and vegetables, or of a number of toxic second-
ary metabolites such as fumonisin and deoxynivalenol,
were amongst those requests, to name a few.
The addition of new terms did not affect the overall
structure of the ontology but helped increase the scope
and coverage of pathway data that the users can access.
In the course of expanding the content of the ontology,
care was taken to appropriately assign terms to the par-
ent or parents to which they belong and to provide ad-
equate definitions. If necessary, new parent terms were
created. Information available at the originating data-
bases and that found in the literature were instrumental
in the process.
Conclusions
The Pathway Portal is an important project at RGD, with
the Pathway Ontology providing the means for both the
standardized annotation of rat, human and mouse genes
and for easy navigation between the components of the
portal and from various entry points. The navigational
aspect is an important one, given the extent of the path-
way data coverage RGD offers. The recent addition of
data import pipelines has helped to further expand the
content of PW and the pathway data RGD provides.
Additional pipelines are envisioned to be built in the
near future. Literature survey continues to be important
for the ongoing development of the Pathway Ontology
and Portal. User requests and external projects using
PW are additional sources for expanding the content of
the ontology and for enhancing its structure. A primary
goal of the Pathway Ontology is to capture the pathway/
network universe and its attributes and to articulate the
connections and relationships between them within a
hierarchical structure. This includes capturing the mal-
functioning of the system and the attempts to restore it.
The five nodes of the ontology along with the provision
of altered pathways address this goal. The branching of
the tree, whether branching within a node or expanding
within a class, does not affect the overall topology and
architecture of the ontology. The literature, external da-
tabases and resources, and expert opinions internally
and externally help assure that the provision of new
terms represents the current knowledge and understand-
ing of biological events and are reflected as such within
the ontology. Table 1 summarizes the structure of the
ontology; Table 2 summarizes the term mappings and
pathway annotations of the two pipelines.
Methods
The Pathway Ontology (PW) is being built using the
OBO-Edit ontology editor, a freely available Java-based
tool developed and maintained by the GO Consortium
[3,29]. Updated versions of the ontology are uploaded
into the database, placed in the RGD ftp site and
uploaded to the NCBO BioPortal PW site (see Abstract,
[30,31]). For the deployment of pipelines, the identifiers
(IDs) used by the external databases are added as syno-
nyms to their corresponding PW terms, in the OBO-
Edit tool.
The pathway diagrams are being built using the Ari-
adne Genomics Pathway Studio version 8, originally
from Ariadne Genomics and currently available at Else-
vier [32]. The tool comes with the mammalian ResNet
database which contains a large set of objects such as
genes, diseases, treatments, chemicals and others along
with their accompanying information. In addition,
ResNet allows for new properties to be added and values
to be attributed to them. These features have been
exploited to add PW and other IDs, as well as urls for
chemicals and for pages containing lists of objects that
are accessible from the diagram pages. These pages are
created using a Content Management System (CMS) – a
computer program for publishing, editing and modifying
content for easier management of workflow. The dia-
grams, saved as HTML, are folders containing the dia-
gram file and files for every object present in the
diagram with the information that object has in the
ResNet database. A script parses these files for PW:IDs,
RGD:IDs and url links that have been added, rendering
these objects linkable to the corresponding sites. The
diagram pages are being created using a web application
developed at RGD [18].
The KEGG and PID pipelines are Java 1.6 standalone
applications. The pipelines communicate with an Oracle
database, the RGD database, using the Oracle JDBC thin
client driver. The Spring framework v.1.2 is used for de-
pendency injection, and parameters are loaded from an
external file allowing for easy pipeline customization
[33]. Apache commons libraries are used for database
connection pooling, and Log4j provides extensive log-
ging capabilities [34]. Database access objects from the
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RGD framework provide a stable data model giving the
pipeline developer a thoroughly tested and efficient API
for accessing the RGD database. The pipeline code is
stored in the RGD subversion code repository. Once a
pipeline is ready to move to production, a job is created
and configured within the Hudson Continuous Integra-
tion Server allowing the pipeline to be rebuilt or de-
ployed directly from source.
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